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Summary: Acutely decompensated heart failure (ADHF) is
characterized by hemodynamic abnormalities and neurohor-
monal activation that contribute to heart failure (HF) symp-
toms, end-organ dysfunction, arrhythmias, and progressive
cardiac failure. The management of ADHF in the emergency
department (ED) can be simplified and improved by a 2-min
bedside assessment that identifies any of four possible hemo-
dynamic profiles on the basis of clinical signs and symptoms.
The profiles are based on whether congestion is present or ab-
sent (wet or dry) and perfusion is adequate or limited (warm or
cold). A wet-warm profile is seen more frequently in the ED
than any of the other three profiles (wet-cold, dry-warm, and
dry-cold). The four clinically determined profiles have been
shown to predict clinical outcomes and may be used to guide
initial HF therapy. The goals of treating ADHF are to stabilize
the patient, reverse acute hemodynamic abnormalities, rapid-
ly reverse dyspnea and/or hypoxemia caused by pulmonary
congestion, and initiate treatments that will decrease disease
progression and improve survival. An ideal agent for the wet-
warm profile would rapidly reduce pulmonary congestion,
produce balanced arterial and venous dilation, promote natri-
uresis, lack direct positive inotropic effects, and not cause re-
flex neuroendocrine activation. Intravenous nesiritide in con-
junction with loop diuretics has been found safe and effective
as initial treatment for patients with the wet-warm profile. For
the wet-cold profile, more intensive therapy and invasive
hemodynamic monitoring may prove useful. This review will
discuss the rapid clinical determination of hemodynamic pro-
files in patients presenting to the ED with ADHF and the 
options for their initial medical management. Case studies
representing the wet-warm, wet-cold, dry-warm, and dry-cold
profiles will be presented and discussed.
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Acronyms
ADHERE® Acute Decompensated Heart Failure Na-
tional Registry
ADHF acutely decompensated heart failure
ANP A-type natriuretic peptide
BNP B-type natriuretic peptide
BUN blood urea nitrogen
CAD coronary artery disease
CCU coronary care unit
CI cardiac index
DCM dilated cardiomyopathy
ECG electrocardiogram
HTN hypertension
JVP jugular venous pressure
LV left ventricular
LVEF left ventricular ejection fraction
OPTIME-CHF Outcomes of a Prospective Trial of Intrave-
nous Milrinone for Exacerbations of Chron-
ic Heart Failure
PCWP pulmonary capillary wedge pressure
PE pericardial effusion
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RF renal failure
RHC right heart catheterization
SVR systemic vascular resistance
VMAC Vasodilation in the Management of Acute
Congestive Heart Failure
Introduction
Patients presenting to the emergency department (ED) 
with acutely decompensated heart failure (ADHF) pose a ma-
jor health care problem.1 They often are hemodynamically un-
stable and have disabling symptoms of dyspnea secondary to
pulmonary congestion. Rapid assessment and treatment are
frequently required to achieve clinical stability and obviate me-
chanical ventilation. After evaluation and stabilization in the
ED, most patients will require hospital admission, although a
low-risk subset may merit discharge following a period of 
observation. The in-hospital mortality for ADHF is 5–8%, the
median duration of hospitalization is 5 days, and the rate of 
rehospitalization over the next 6 months is as high as 50%.1, 2
From the years 1979 to 2000, the combined number of ED vis-
its and subsequent rehospitalizations for ADHF increased from
377,000 to 999,000.2 The estimated annual expenditure for in-
patient management of ADHF is $12.7 billion.2
The goals in managing ADHF are to reverse acute hemody-
namic abnormalities, rapidly relieve symptoms, and initiate
treatments that will decrease disease progression and improve
survival (Table I). In the past, ADHF was often viewed as
merely a disorder of volume overload and low cardiac output.
Early treatment strategies that focused on efforts to maximize
cardiac output led to increased mortality.3 Monotherapy with
intravenous (IV) diuretics led to further increases in systemic
vascular resistance (SVR) and additional deleterious neuro-
hormonal activation.4 It is now recognized that ADHF encom-
passes a range of hemodynamic profiles that can be clinically
characterized to guide therapy. In most cases, ADHF is char-
acterized by elevated left ventricular (LV) filling pressures
(congestion) that reflect a combination of increased SVR and
insufficient systolic and diastolic myocardial functional re-
serve.3, 5, 6 This realization has shifted the treatment emphasis
from diuretic monotherapy and/or IV inotropic agents to IV
natriuretic peptides and vasodilators in combination with di-
uretics.5 This more physiologic approach has been shown to
relieve symptoms more rapidly and reduce morbidity more
effectively. Thus, it has the potential to curb rising health
care costs by reducing admissions, length of stay (LOS), and
rehospitalization.
Hemodynamic Mechanisms in Acutely
Decompensated Heart Failure
Until recently, the pathogenesis of ADHF was attributed to
impaired contractility (systolic failure) and fluid accumula-
tion in the lungs secondary to systemic volume overload.6 It 
is now recognized that (1) no change in LV ejection fraction
(LVEF) occurs with acute decompensation of chronic heart
failure (HF) or after its reversal;5, 6 (2) LV function is entire-
ly normal in up to half of patients hospitalized for ADHF;6
and (3) while decompensation of HF and pulmonary edema
are almost always accompanied by elevated LV filling pres-
sures and SVR, cardiac index (CI) may be low, normal, or in-
creased.5 Decompensation of HF and pulmonary edema may
develop rapidly, within minutes or even over a few hours.
Therefore, net fluid accumulation cannot be the sole mecha-
nism of pulmonary edema. Recent data instead implicate a
process in which a portion of the intravascular volume is re-
distributed to the lungs.5, 6 Increases in SVR contribute to this
rapid redistribution of fluid. Gandhi et al. found that echocar-
diographic LVEF was almost within normal range (LVEF =
0.50 ± 0.15) in patients presenting to the ED with pulmonary
edema.6 The most significant finding during acute pulmonary
edema was diastolic dysfunction and elevated SVR.6 Thus,
peripheral vasoconstriction plays a major role in the process
of decompensation in systolic and isolated diastolic dysfunc-
tion. In ADHF, an inappropriate increase in SVR is met with
insufficient systolic and diastolic myocardial functional re-
serve.5 This afterload mismatch causes a vicious cycle of events
that sequentially includes atrioventricular valvular regurgita-
tion, a decrease in forward stroke volume, and an increase in
LV diastolic pressure. The increased LV diastolic pressure is
transferred backward to the pulmonary veins, leading to pul-
monary edema. Thus, the primary pathophysiologic mecha-
nism of ADHF is elevation of LV filling pressure and fluid 
redistribution to the lungs as a result of afterload mismatch (ex-
cess vasoconstriction) rather than decrease in contractility.
These hemodynamic alterations contribute to the symptoms,
functional limitations, and clinical decompensation that result
in ED visits and hospitalizations.3, 5
The hemodynamic parameter most closely related to
symptoms of decompensation of HF and adverse clinical out-
comes is elevation in LV filling pressures. Persistent elevation
in LV filling pressures has been associated with an increased
risk of progressive HF, sudden death, and overall mortality in
patients hospitalized with decompensated HF. In a study of
1,156 patients hospitalized with ADHF due to systolic 
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TABLE I Therapeutic goals in acutely decompensated heart failure
Goals Endpoints or methods
Rapidly reverse acute Lower pulmonary capillary 
hemodynamic abnormalities wedge pressure
Rapidly relieve symptoms and Relief of dyspnea 
improve respiratory status and/or hypoxemia
Initiate treatment that will Use of ACE inhibitors, 
slow disease progression beta blockers, and aldosterone 
and improve long-term antagonists prior to 
survival hospital discharge
Apply treatments cost Shortened EMC and hospital 
effectively LOS, minimal use of ICU/CCU
Abbreviations: ACE = angiotensin-converting enzyme, CCU = coro-
nary care unit, EMC = emergency medical care, LOS = length of stay,
ICU = intensive care unit.
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dysfunction (mean LVEF = 0.20 ± 0.07) and treated with IV
vasodilators and diuretics, the achievement of near-normal
LV filling pressures (pulmonary capillary wedge pressure
[PCWP] < 16 mmHg) resulted in a 1-year survival of 82%
compared with only 65% (p = 0.00001) in patients with per-
sistently elevated LV filling pressures (PCWP > 18 mmHg)
(Fig. 1).7 Hemodynamic measures at baseline such as right
atrial pressure, pulmonary arterial pressure, systemic arterial
pressure, CI, and heart rate were not predictive of mortality.7
Multivariate analysis showed that independent predictors of
total mortality at 1 year were a high PCWP (p = 0.001), low
serum sodium (p = 0.002), increased LV end-diastolic dimen-
sion (p = 0.01), and low peak oxygen consumption on car-
diopulmonary exercise testing (p = 0.001).7 Contrary to con-
ventional expectations, changes in CI have not been found
predictive of outcome (Fig. 2).7, 8 It has also been shown that
even at levels below symptom threshold, elevated PCWP pre-
dicts worse outcome in patients with HF.8 B-type natriuretic
peptide (BNP), which is released from the cardiac ventricles
in response to pressure or volume stimulus,9 is elevated in pa-
tients with HF and closely correlates with elevated LV filling
pressures. Levels of BNP have also been shown to predict 
independently rehospitalization or death in patients hospital-
ized with HF.10 Elevations of LV filling pressure (whether de-
termined by biologic assay or direct hemodynamic measure-
ment, or inferred by symptoms of orthopnea) are associated
with increased symptoms, more frequent hospitalizations,
and increased mortality.5
Clinical Assessment of Hemodynamic Profiles
The rapid clinical assessment of patients with ADHF has
been simplified by the introduction of a 2-min bedside exami-
nation that relies on physical signs and symptoms to determine
which of the four possible hemodynamic profiles is present.
This assessment, based on findings by Forrester et al. in pa-
tients with acute myocardial infarction,11 has been described
by Nohria et al.12 The earlier work established correlations 
between clinical findings and hemodynamic measurements
(PCWP and CI) that were obtained by Swan-Ganz catheteri-
zation. In addition, Forrester et al. showed that, in patients with
acute myocardial infarction, physical findings could be used to
identify four hemodynamic profiles that were predictive of
short-term survival.11 It has recently been shown that the
classification of patients with advanced HF by these same
four hemodynamic profiles can be used to predict early and
late mortality.12
The assessment of patients with HF is based on whether
clinical symptoms indicate that filling pressure is or is not ele-
vated (wet or dry) and perfusion is or is not adequate (warm or
cold), with combinations of these parameters yielding four
possible hemodynamic profiles (Fig. 3). It relies on symptoms
that have been shown to predict pulmonary artery catheter
measurements that define congestion (wet) and hypoper-
fusion (cold); a PCWP≥18 mmHg and a CI ≤2.2 l/min/m2,
respectively.12 More than 80% of patients presenting to the
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FIG. 1 Kaplan-Meier survival for 1,156 patients with acutely de-
compensated heart failure who are subgrouped for response to treat-
ment, as defined by quartiles of pulmonary capillary wedge pressure
(PCWP). On multivariate analysis, PCWP was an independent pre-
dictor of mortality, but resting cardiac index was not.7
FIG. 2 Hemodynamic assessment in 456 heart failure patients after tailored therapy. In-hospital pulmonary capillary wedge pressure was pre-
dictive of subsequent mortality (p = 0.001), whereas cardiac index was not.
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ED with ADHF have clinical congestion (i.e., are classified as 
being wet) and, if right heart catheterization were performed,
would show elevated PCWP.3 These patients may have ade-
quate (wet-warm) or reduced (wet-cold) perfusion, with the
majority showing elevation in SVR. Clinical indicators of
congestion in the assessment of patients with HF include a 
recent history of orthopnea and/or evidence on physical exam
of jugular venous distention, hepatojugular reflux, ascites,
periperal edema, leftward radiation of the pulmonic heart
sound, or a square wave blood pressure response to the Valsal-
va maneuver.12 These indicators vary in utility. Rales are en-
tirely absent in more than 80% of patients with chronically el-
evated filling pressures due to compensation of the pulmonary
lymphatics.3 Peripheral edema is a relatively insensitive indi-
cator of elevated filling pressures in patients with HF and may
have a noncardiac cause. A third heart sound may or may not
be detected.3 A patient with ADHF without congestion (dry)
may have adequate (dry-warm) or compromised (dry-cold)
perfusion. Compromised perfusion (cold) is indicated by a
narrow proportional pulse pressure ([systolic – diastolic blood
pressure]/systolic blood pressure < 25%), pulsus alternans,
symptomatic hypotension in the absence of orthostasis, cool
extremities, and/or impaired mental status.12 The most assess-
able indicators of perfusion are blood pressure and pulse pres-
sure.3 In the assessment described by Nohria et al., physicians
synthesize findings on the presence or absence of the clinical
indicators to make a subjective determination of the hemody-
namic profile.12
The prognostic utility of the clinical profiling method was
prospectively evaluated in 452 consecutively hospitalized pa-
tients with HF, 49% of whom had an admitting diagnosis of
decompensated HF.12 At baseline, 123 (27%) were classified
as dry and warm, 222 (49%) as wet and warm, 91 (20%) as
wet and cold, and 16 (4%) as cold and dry.12 The profiles were
predictive of outcome. Patients with the dry and warm profile
had a low 6-month mortality relative to the three other profile
groups (Table II).12 Profiles wet and warm and wet and cold
were independently associated with increased risk of death or
cardiac transplant by univariate analysis (p = 0.02 and 0.003,
respectively), and these two profiles were also independent
predictors of the same endpoint (hazard ratio [HR] 1.83, p =
0.02; HR 2.48, p = 0.002, respectively).12
Modification of Clinical Profiles to Include the 
Cardio-Renal Syndrome
Increasingly, a significant number of patients with the wet
and warm profile or wet and cold profile present with renal
dysfunction. Elevated serum creatinine is an independent neg-
ative prognostic indicator in patients admitted with decom-
pensated HF.13, 14 Furthermore, preexisting renal dysfunction
is a key predictor for developing worsening renal function
during the treatment of decompensated HF.15 A deterioration
in renal function as a consequence of HF therapy has been as-
sociated with increased LOS and increased mortality.15, 16
Therefore, special attention must be given to patients with re-
nal dysfunction.
Treatment Strategies
The hemodynamic classification system may prove useful
as a guide to initial therapy in patients with ADHF. An ideal
agent for a patient with ADHF and congestion (wet and warm
or wet and cold profile) would be one that rapidly reduces
PCWP and consequently relieves symptoms of congestion
and hypoxia, produces balanced arterial and venous dilation,
promotes natriuresis, lacks direct positive inotropic effects,
and does not cause reflex neurohormonal activation (Table
III).5 The initial treatment options for decompensated HF in-
clude IV loop diuretics, inotropic agents, vasodilators, and the
natriuretic peptides.
Intravenous Loop Diuretics
Despite having been used as front-line therapy in patients
with ADHF for many decades, IV loop diuretics have been
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TABLE II Six-month mortality by clinically determined hemody-
namic profiles12
Patient profile N (%) Six-month mortality (%)
Dry-warm 123 (27) 11
Wet-warm 222 (49) 22
Wet-cold 91 (20) 40
Dry-cold 16 (4) 17
FIG. 3 Rapid clinical assessment of hemodynamic profiles. Bedside
physical findings can be used to classify patients into four hemody-
namic profiles based on whether the findings indicate a pulmonary
capillary wedge pressure (PCWP) that is normal or elevated (conges-
tion) and a cardiac index (CI) that is normal or decreased (low perfu-
sion). Patients hospitalized with acutely decompensated heart failure
usually have evidence of congestion (wet-warm or wet-cold).
Patients with a wet-warm profile are ideally treated with intravenous
nesiritide or another vasodilator in conjunction with an intravenous
loop diuretic. SVR = systemic vascular resistance.
Congestion
Low
perfusion
Natriuretic
peptides
• Nesiritide
Vasodilators
• Nitroprusside
• Nitroglycerin
No
No
Yes
Dry-warm
PCWP normal,
CI normal
Yes
Wet-warm
PCWP elevated,
CI normal
normal SVR
Inotropic drugs
• Dobutamine
• Milrinone
high SVR
Dry-cold
PCWP low/normal,
CI decreased
Wet-cold
PCWP elevated,
CI decreased
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sparsely studied in this role.4 Acute use of IV furosemide caus-
es a significant decrease in PCWP and right atrial pressure, an
effect attributable to both venodilation and diuresis.4 Concom-
itant effects, however, include a decrease in stroke volume, an
increase in SVR, and pronounced neurohormonal activation.17
Increases in activation of the renin-angiotensin-aldosterone
system and the sympathetic nervous system (as reflected 
by plasma norepinephrine levels) occur shortly after a single
IV dose of furosemide.17 In a comparative trial, patients on
high-dose IV loop diuretics did significantly worse than did
patients on a combination of a low-dose counterpart and an IV
vasodilator in all primary and secondary outcome measures,
including need for mechanical ventilation (40 vs. 13%, p =
0.004).18 By causing further neurohormonal activation and
systemic arterial constriction, IV loop diuretics prevent nor-
malization of ventricular filling pressures and limit relief of
HF symptoms, setting the stage for early rehospitalization.
The deleterious effects of diuretic therapy on neurohor-
monal activation can also lead to renal vasoconstriction and
decreased renal perfusion. While diuretics increase urinary
volume, they often do so at the expense of decreased renal
clearance.19 This decline in the glomerular filtration rate not
only results in decreased delivery of sodium and water, but
also decreased delivery of diuretic medications. These effects
can translate into diuretic refractoriness and progressive renal
dysfunction. The development of renal dysfunction often
leads to withdrawal of angiotensin-converting enzyme (ACE)
inhibitors and diuretics until the creatinine normalizes, and
frequently the patient is discharged with persistent volume
overload and symptoms. A retrospective analysis of 48 pa-
tients hospitalized with decompensated heart failure demon-
strated that 21% develop worsening renal dysfunction (mean
creatinine 1.6 ± 0.3 to 2.6 mg/dl) as a consequence of diuretic
therapy for decompensated heart failure.15 This rise in creati-
nine was associated with an increased LOS (9 to 17 days) and
increased mortality (relative risk [RR] 5.3).15 Thus, IV loop
diuretics may be required to reduce congestion in patients
who are of the wet and warm profile and wet and cold profile,
but may be more effective when combined with IV natriuret-
ic peptides or vasodilators. 
Inotropic Agents
The main effect of IV inotropic therapy in HF is to improve
CI. Moreover, the use of IV inotropes in HF has been linked to
an increased frequency of adverse events and, in some trials,
increased mortality.20 The Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations of Chronic Heart
Failure (OPTIME-CHF) study randomized 949 patients hos-
pitalized with ADHF to treatment with placebo or a 48-h 
infusion of milrinone (0.5 mcg/kg/min) and found that the 
inotropic agent did not reduce LOS and was associated with a
significantly greater frequency of adverse events (13 vs. 2%,
p<0.001) and a trend toward increased mortality (4 vs. 2%).21
Compared with milrinone, the inotropic agent dobutamine is
less likely to cause hypotension and is much less expensive,
but it also increases heart rate and the risk of developing 
arrhythmias. Dopamine is frequently infused at low doses to
attempt to improve renal blood flow and diuresis, but clinical
trials have failed to demonstrate increases in urine output.
Positive inotropic agents pose risks of aggravating ischemia
and arrhythmias. Weaning from inotropic support is often nec-
essarily slow, potentially prolonging hospitalization, and may
necessitate complex adjustment of concomitant oral regimens.
Prolonged physiologic effects of inotropic infusions during
hospitalization may mask inadequacy of a diuretic regimen and
intolerance to vasodilator doses, setting the stage for readmis-
sion.3 There is concern that the use of inotropes upon admission
for decompensated HF may create inotrope dependence. Trials
of outpatient use of dobutamine, milrinone, vesnarinone, enox-
imone, and xamoterol have shown increased mortality com-
pared with placebo.20
Although the risk–benefit ratio of inotropic infusion is un-
favorable for the majority of patients presenting with decom-
pensated HF, this therapy can be life saving in patients with
cardiogenic shock. Moreover, brief inotropic therapy may be
appropriate for patients with acute decompensation and the
dry and cold or wet and cold profile.3
Intravenous Vasodilators
There is a relatively sound physiologic rationale for using
IV vasodilators to reverse acute HF decompensation, since
such therapy primarily targets elevations of ventricular filling
pressures and SVR.5 Intravenous vasodilator therapy has not
been associated with a worsening of myocardial ischemia (and
actually reduces myocardial oxygen consumption) or the pre-
cipitation of ventricular arrhythmias,3 and can ease and speed
the transition to an oral regimen of an ACE inhibitor and di-
uretic.22 A significant reduction (and near normalization) in
ventricular filling pressures can be achieved with IV vasodila-
tors and diuretics within 3 to 24 h in decompensated patients
with HF with the wet and warm profile and the wet and cold
profile with elevated SVR. These improved hemodynamics
can be maintained over the following 8 months with an oral
regimen of an ACE inhibitor and a diuretic.23 Thus, IV va-
sodilators promote the rapid reversal of decompensation with
complete or near normalization of resting hemodynamics that
can then be maintained long term with an oral HF medical reg-
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TABLE III Characteristics of an ideal agent for patients with acute-
ly decompensated heart failure and congestion (wet-warm or wet-
cold profile)
• Produces vasodilation (venous and arterial)
• Rapidly decreases ventricular filling pressures
• Rapidly decreases symptoms of congestion 
• Does not increase heart rate or directly increase contractility 
(decreases myocardial oxygen demand)
• Is not proarrhythmic
• Does not cause tachyphylaxis
• Provides neurohormonal suppression 
• Promotes diuresis and natriuresis
• Is conveniently dosed (can be used with or without invasive 
hemodynamic monitoring)
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imen.24 The vasodilator strategy can also facilitate the more
rapid initiation and titration of other survival-enhancing HF
medications, such as beta blockers, by promoting the rapid
resolution of volume overload.
Sodium nitroprusside, a potent direct vasodilator, rapidly
lowers filling pressures through venous and arterial vasodi-
lation, with increases in cardiac output and consequent im-
provement in response to IV diuretics.3 However, the admin-
istration of nitroprusside requires invasive monitoring with a
pulmonary artery catheter in a cardiac care unit with suitably
trained nurses and a staff capable of frequent dose titration.
Monitored nitroprusside infusion rarely causes symptomatic
hypotension, but is occasionally complicated by cyanide tox-
icity, the risk of which increases with dose, duration, and hep-
atic and renal dysfunction. In addition, nitroprusside has been
shown to reduce renal perfusion in patients with preexisting
renal dysfunction.25
Intravenous nitroglycerin, which causes arterial and venous
dilation in patients with ADHF, has not undergone extensive
clinical evaluation in this role. The Vasodilation in the Manage-
ment of Acute Congestive Heart Failure (VMAC) trial showed
a reduction in filling pressures with IV nitroglycerin compara-
ble with placebo when added to standard care.26 Headache as a
side effect can limit the use of this agent. Dosing can be guided
with or without invasive hemodynamic monitoring. Frequent
up-titration in dose is required to achieve adequate symptomat-
ic response. With higher doses of IV nitroglycerin, early tachy-
phylaxis has been seen.27 The effect of nitroglycerin on neuro-
hormonal activation has not been well studied.
Natriuretic Peptides
Endogenously generated natriuretic peptides, such as 
A-type natriuretic peptide (ANP) and B-type natriuretic pep-
tide (BNP), are activated in response to atrial and ventricular
pressure or expansion. The natriuretic peptide system counter-
regulates the sympathetic nervous system and has been shown
to decrease plasma levels of epinephrine, aldosterone, and en-
dothelin.28 When stimulated, natriuretic peptide receptors ac-
tivate guanylyl cyclase, causing an increase of intracellular
cyclic guanosine monophosphate (cGMP) at the target organ,
which mediates some of their effects. Studies have shown that
BNP produces balanced vasodilation as well as some degree
of natriuresis and lusitropy.28 A rare property of natriuretic
peptides is the ability to reduce LV filling pressures without an
increase in heart rate or myocardial oxygen demand.29
Nesiritide is a recombinant form of human BNP approved
for treatment of ADHF.26, 30 It possesses many of the charac-
teristics of an ideal agent for treating patients with ADHF, par-
ticularly those of the wet and warm profile (Table III). The IV
administration of nesiritide has been shown to produce favor-
able hemodynamic effects, including balanced vasodilation
associated with a rapid improvement in HF clinical symptoms.
Administration of nesiritide produces a dose-related reduction
in ventricular filling pressures and augmentation of LV stroke
volume due to afterload reduction.26 These effects appear to be
sustained during continuous administration over 48 h and,
compared with nitroglycerin, nesiritide produces more rapid
reduction in PCWP and fewer adverse effects. The VMAC tri-
al demonstrated that a 2 mcg/kg IV bolus given over 1 min fol-
lowed by a fixed infusion of 0.01 mcg/kg/min reduces PCWP
rapidly, significantly, and safely while improving self-reported
scores on dyspnea index scales in patients who do or do not
undergo monitoring of central hemodynamics by pulmonary
artery catheter.26 In this study, nesiritide was added to standard
therapy (including dobutamine, dopamine, and parenteral di-
uretics) in patients hospitalized with ADHF due to a wide va-
riety of causes. Compared with placebo plus standard care, ne-
siritide plus standard care produced greater hemodynamic and
clinical benefits with fewer adverse effects.
Nesiritide may be started simultaneously with, or just prior
to, IV diuretic therapy during the initial presentation of patients
with ADHF and a wet and warm profile. It can be administered
to wet and cold profile patients in conjunction with dopamine
or inotropic agents such as dobutamine if these other agents are
indicated. Nesiritide can be safely administered in the ED, ob-
servation unit, inpatient-telemetry or step-down unit, or other
settings that generally cannot provide intensive monitoring.26
Proarrhythmia has not been observed, and ventricular arrhyth-
mias,31 ventricular tachycardia events per 24 h,32 repetitive
ventricular beats/h,32 and premature ventricular beats/h32 occur
much less commonly with nesiritide than with inotropic agents
such as dobutamine. This is important because a history of ven-
tricular arrhythmia is common among patients with acute HF.
Whereas inotropic agents have been associated with increases
in the incidence of myocardial infarction and in mortality in pa-
tients with coronary artery disease, nesiritide has not.26 In the
VMAC trial, symptomatic hypotension occurred in 4 and 5%
of patients treated with nesiritide and nitroglycerin, respective-
ly.26 Nesiritide-induced hypotension caused no adverse seque-
lae and was easily reversed (fluid administration and/or patient
repositioning). With a half-life of 15 to 20 min, nesiritide
should not be titrated at frequent intervals as is done with other
IV agents that have a shorter half-life.
Guiding of Initial Treatment by Clinical Profiles
Recent data suggest that both the timing and choice of 
initial therapy in the ED can have a significant impact on a pa-
tient’s hospital course and clinical outcome, as well as inten-
sity of care required. Early initiation of IV vasoactive medi-
cations appears to decrease inpatient LOS. From the Acute
Decompensated Heart Failure National Registry (ADHERE®),
patients who received vasoactive therapy in the ED had an
overall LOS of 3.0 days, compared with 7.0 days if treatment
was delayed until inpatient unit arrival (p < 0.0001).33 A sim-
ilar pattern was seen in the intensive/coronary care unit (ICU/
CCU), where those patients treated with vasoactives in the
ED showed a significantly shorter LOS than did those receiv-
ing in-hospital treatment (2.1 vs. 4.5 days, p < 0.0001).33 Be-
cause a majority of patients with HF are seen initially in the
ED, methods must be developed for the rapid identification of
patients likely to benefit from early vasoactive therapy.33
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For patients in the most common hemodynamic profile
(wet and warm), the immediate goal of therapy is symptom
relief and lowering of ventricular filling pressures (Table I).
These patients are ideal candidates for nesiritide in conjunc-
tion with IV loop diuretics. Patients with the wet and cold
profile may require more intensive therapy to achieve ade-
quate diuresis, perhaps even with guidance by invasive
hemodynamic measurements. These patients may have low
cardiac output in the setting of elevated SVR and still re-
spond well to natriuretic peptides or vasodilators in conjunc-
tion with diuretics (Fig. 3). Wet and cold profile patients
with decreased or normal SVR may be good candidates for
short-term inotropic therapy. The dry and warm profile pa-
tients have a good prognosis, do not require IV therapy, may
not require hospitalization, and merit investigation of
whether symptoms are due to non-ADHF causes (Fig. 4).
Patients with the very uncommon dry and cold profile may
benefit from a decrease or withdrawal of recently initiated
beta blockers until better compensation is achieved. Bedside
clinical profiling can also be used as a prognostic tool that
guides triage decisions.
Optimization of Oral Heart Failure Therapies
After reversal of acute decompensation, comprehensive
neurohormonal blockade with ACE inhibitors, beta blockers,
and aldosterone antagonists can be initiated or dose adjusted
V-7
FIG. 4 Assessment and treatment algorithm for acutely decompensated heart failure. Initial heart failure treatment can be guided on the basis of
the clinically assessed hemodynamic profiles. ACE = angiotensin-converting enzyme, ACS = acute coronary syndrome, CAD = coronary artery
disease, BNP = B-type natriuretic peptide, CXR = chest x-ray, DCM = dilated cardiomyopathy, ECG = electrocardiogram, HF = heart failure,
HTN = hypertension, ICU = intensive care unit, IV = intravenous, PE = pericardial effusion, RHC = right heart catheterization, minimal use of
ICU/CCU, SVR = systemic vascular resistance.
Suspicion of heart failure
History and physical exam
• Considerations: HF history, chest pain, CAD, DCM, HTN, infection, anemia
Rapid clinical assessment of hemodynamic profiles
• Congestion: yes or no
• Perfusion decreased: yes or no
Helpful diagnostic findings
• ECG: ischemia or arrhythmias
• CXR: congestion and/or cardiomegaly
• Establish diagnosis
• Initiate treatment based on clinical 
assessment of hemodynamic profile
Dry-warm profile
Initial management
• Continue oral heart
failure medications
• Search for other
causes of symptoms
including PE, ACS,
depression, anemia,
hypothroidism
Wet-warm profile
Initial management
• IV loop diuretics
• IV nesiritide or 
IV vasodilator
• Oxygen, if indicated
Admit: Telemetry or
observation unit
Wet-cold profile
Initial management
• IV loop diuretics
• Consider RHC if 
high SVR
• IV nesiritide or IV
vasodilator if high SVR
• Inotropes or pressor 
if low SVR
Admit: ICU or 
telemetry unit
Dry-cold profile
Initial management
• Continue RHC
• Inotrope and/or
pressor 
• Consider decrease of
beta blocker dose
Admit: ICU or 
telemetry unit
Upon compensation optimize oral heart failure medications 
(ACE inhibitors, beta blockers, aldosterone antagonist, 
evaluate/manage comorbidities, assess sudden death risk, optimize 
HR patient education, optimize discharge planning and follow-up care)
Discharge
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to reduce disability or risk of hospitalization and death fur-
ther.1 Patients should be assessed for significant comorbidi-
ties, potential need for revascularization, and risk of sudden
death. Nonpharmacologic therapy should be optimized and
patient education provided prior to discharge.1, 24 When com-
bined with a comprehensive HF management program, the
use of IV vasodilators to normalize ventricular filling pressure
and oral HF medications to maintain this effect has been asso-
ciated with an 85% reduction in hospitalization and improved
functional capacity compared with conventional HF manage-
ment.24 The ED use of IV nesiritide as initial treatment to 
reverse decompensation rapidly may allow for earlier admin-
istration of beta blockers and other HF therapies that are con-
traindicated during decompensation. Thus, emergency physi-
cians can contribute critically to the optimal management of
ADHF by providing rapid diagnosis and initial therapy that
will rapidly reverse decompensation and, in consequence, 
facilitate the initiation of evidence-based, guideline-recom-
mended therapy for chronic HF (Table I).
Conclusions
In patients presenting with ADHF, elevated LV filling pres-
sure and SVR directly contribute to fluid redistribution, pul-
monary edema, and respiratory compromise. The rapid clini-
cal assessment of patients with ADHF can be simplified by
considering four possible hemodynamic profiles. Of these,
the wet and warm profile is seen most commonly in the ED.
While LV filling pressure is highly predictive of HF symptoms
and clinical outcomes, resting CI is not. The traditional focus
on acute maximization of cardiac output led to therapies that
increased mortality. Hemodynamic optimization with rapid
reduction in LV filling pressures and SVR appears to be the
most important therapeutic goal for achieving clinical stability
and reducing the long-term risk of fatal decompensation and
sudden death in HF.
Nesiritide possesses many characteristics of an ideal agent
for treating patients with ADHF. There is now compelling ev-
idence supporting the initial use of nesiritide as opposed to in-
otropic agents or high-dose IV loop diuretic monotherapy for
ADHF if cardiogenic shock is absent. After rapid reversal of
decompensation, comprehensive neurohormonal blockade
can be initiated to reduce disability and the risk of hospitaliza-
tion and death further. The ED use of optimal pharmacologic
treatment for HF can have a significant impact upon patient
outcomes and resource utilization.
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